Copyright
©The Author(s) 2023.
World J Gastroenterol. Feb 21, 2023; 29(7): 1139-1156
Published online Feb 21, 2023. doi: 10.3748/wjg.v29.i7.1139
Published online Feb 21, 2023. doi: 10.3748/wjg.v29.i7.1139
Ref. | Disease | Type of study | n | Application | Outcomes |
Cross et al[21] | IBD | Noncontrolled, clinical trial | 10 | Telemonitoring, home unit-server PC provider | Feasible method |
Excellent patient acceptance | |||||
Cross et al[113] | IBD | Noncontrolled clinical trial | 25 | Telemonitoring, home unit-server PC provider | Feasible method |
Excellent patient acceptance | |||||
Improvement in QoL, disease activity, and disease knowledge | |||||
Cross et al[42] | UC | Controlled randomized clinical trial | 47 | Telemonitoring, home unit-server PC provider | Feasible method |
Excellent patient acceptance | |||||
Improvement in QoL | |||||
Elkjaer et al[115] | UC | Validation study in 2 groups | 21 | Telemonitoring through the web | Feasible method |
Excellent patient acceptance | |||||
Elkjaer et al[22] | UC | Controlled randomized clinical trial | 333 | Telemonitoring through the web | Feasible method |
Excellent patient acceptance | |||||
Improvement in QoL, disease knowledge, and adherence | |||||
Pedersen et al[10] | CD | Pilot study, controlled | 27 | Telemonitoring through the web | Feasible and safe method for individualized scheduling of maintenance IFX treatment |
Pedersen et al[11] | UC | Prospective noncontrolled study | 95 | Telemonitoring through the web | Feasible and improve adherence to therapy |
Torrejón et al[56] | IBD | Descriptive, observational, retrospective | 1784 | Telecare through e-mail, phone calls, fax | Increased telematic contacts and decreased in-person care |
Johnson et al[27] | IBD | Telemonitoring project | 420 | A web-guided programme | Effective, safe and cost savings |
De Jong et al[24] | IBD | Controlled randomized clinical trial | 909 | Telemonitoring through the web (mHealth) | Reduced outpatient visits and hospitalizations |
Carlsen et al[43] | IBD | Controlled randomized clinical trial | 53 | Telemonitoring through the web (mHealth) | Reduced outpatient visits |
No differences in disease activity, QoL or adherence compared with standard care | |||||
Walsh et al[112] | UC | Pilot study, non controlled | 66 | Telemonitoring through the web (mHealth) | Feasible and usable to measure disease activity, QoL and medication use |
Del Hoyo et al[52] | IBD | Controlled randomized clinical trial | 63 | Telemonitoring through the web | Higher improvement in disease activity compared to usual care |
Similar improvement in QoL, social activities and satisfaction between groups | |||||
Cross et al[25] | IBD | Controlled randomized clinical trial | 348 | Telemonitoring through the web (mHealth) | Improvement in disease activity and QoL, although not superior to usual care |
Decrease in hospitalizations and increase in distance contacts | |||||
Bilgrami et al[48] | IBD | Controlled randomized clinical trial | 222 | Telemonitoring through the web (mHealth) | No differences in self-efficacy or patient activation compared with standard care |
Schliep et al[47] | IBD | Controlled randomized clinical trial | 217 | Telemonitoring through the web (mHealth) | No significant improvement in depressive symptoms or QoL compared with standard care |
Heida et al[45] | IBD | Controlled randomized clinical trial | 170 | Telemonitoring through the web, e-mail and telephone | Similar improvement in QoL compared to conventional care |
Reduction in outpatient visits and societal costs | |||||
Satisfaction | |||||
Linn et al[46] | IBD | Controlled randomized clinical trial | 160 | Telemonitoring through the web or SMS combined with tailored counselling | Improved self-efficacy |
Satisfaction | |||||
Bonnaud et al[51] | IBD | Controlled randomized clinical trial | 54 | Telemonitoring through the web (mHealth) | Significant improvement in QoL |
A trend to reduce outpatient visits | |||||
Satisfaction | |||||
McCombie et al[50] | IBD | Controlled randomized clinical trial | 100 | Telemonitoring through the web (mHealth) and home-based FC | Non-inferiority of QoL and symptoms |
Reduced outpatient visits |
- Citation: Del Hoyo J, Millán M, Garrido-Marín A, Aguas M. Are we ready for telemonitoring inflammatory bowel disease? A review of advances, enablers, and barriers. World J Gastroenterol 2023; 29(7): 1139-1156
- URL: https://www.wjgnet.com/1007-9327/full/v29/i7/1139.htm
- DOI: https://dx.doi.org/10.3748/wjg.v29.i7.1139